The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer.
The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer.
“Biosimilars are of growing importance to the oncology community and the approval of Herzuma may provide more patients access to this important therapy,” said Woosung Kee, CEO of Celltrion, in a statement announcing the approval. “This is our second oncology biosimilar approval in the United States in the past month, which reinforces the goal for all of our approved products—providing broader treatment options for patients and the providers who treat them.”
Approval of the drug was based on a data package that included efficacy, safety, immunogenicity, pharmacodynamic, and pharmacokinetic data from trials conducted in over 500 patients in 22 countries. A phase 3 equivalence trial of the biosimilar as a neoadjuvant treatment in HER2-positive early breast cancer demonstrated equivalent efficacy of the proposed biosimilar with the reference trastuzumab, with a similar proportion of patients achieving pathological complete response in the trial’s 2 arms.
A similar proportion of patients receiving the biosimilar and the reference experienced serious treatment-emergent adverse events (TEAEs) (7% in the biosimilar group versus 8% in the reference group), with the most frequently reported TEAE being neutropenia (4% versus 5%, respectively).
The approval of the drug follows disappointment for Celltrion earlier this year; in April 2018, the FDA issued a Complete Response Letter (CRL) for Herzuma following a Form 483 that noted 12 observations related to the company’s manufacturing process. After working together with the regulator to address the issues found in the CRL, Celltrion resubmitted its Biologics License Application for the drug in June 2018.
While the reference product is also approved for the treatment of HER2-positive gastric cancer, Herzuma did not gain approval in this indication. Earlier this year, the FDA also approved Celltrion’s rituximab biosimilar, Truxima, with a “skinny label” that included fewer indications than its reference. At the time, Celltrion indicated that it had elected to seek fewer than all indications for its product due to intellectual property issues.
Herzuma is the second FDA-approved trastuzumab biosimilar, following Mylan and Biocon’s approval for Ogivri in December 2017 (Ogivri has not yet launched in the United States). Herzuma has also earned approval in the European Union (where it is marketed by Mundipharma), in Japan (where it is marketed by Daiichi Sankyo), and in Australia.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.